Your browser doesn't support javascript.
loading
Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells.
Neo, Shi Yong; Jing, Xu; Tong, Le; Tong, Dongmei; Gao, Juan; Chen, Ziqing; De Los Santos, Mireia Cruz; Burduli, Nutsa; De Souza Ferreira, Sabrina; Wagner, Arnika Kathleen; Alici, Evren; Rolny, Charlotte; Cao, Yihai; Lundqvist, Andreas.
Afiliación
  • Neo SY; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Jing X; Singapore Immunology Network SIgN, Agency for Science Technology and Research, Singapore.
  • Tong L; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  • Tong D; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Gao J; Centre for Innate Immunity and Infectious Disease, Hudson Institute of Medical Research, Melbourne, Victoria, Australia.
  • Chen Z; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  • De Los Santos MC; Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China.
  • Burduli N; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • De Souza Ferreira S; Department of Molecular Biology, Princeton, Princeton, New Jersey, USA.
  • Wagner AK; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Alici E; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Rolny C; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Cao Y; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Lundqvist A; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
J Immunother Cancer ; 10(10)2022 10.
Article en En | MEDLINE | ID: mdl-36283735
ABSTRACT
Downregulation of MHC class I (MHCI) molecules on tumor cells is recognized as a resistance mechanism of cancer immunotherapy. Given that MHCI molecules are potent regulators of immune responses, we postulated that the expression of MHCI by tumor cells influences systemic immune responses. Accordingly, mice-bearing MHCI-deficient tumor cells showed reduced tumor-associated extramedullary myelopoiesis in the spleen. Depletion of natural killer (NK) cells abrogated these differences, suggesting an integral role of immune-regulatory NK cells during tumor progression. Cytokine-profiling revealed an upregulation of TNF-α by NK cells in tumors and spleen in mice-bearing MHCI expressing tumors, and inhibition of TNF-α enhanced host myelopoiesis in mice receiving adoptive transfer of tumor-experienced NK cells. Our study highlights a critical role of NK cells beyond its identity as a killer lymphocyte and more importantly, the potential host responses to a localized tumor as determined by its MHCI expression.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Mielopoyesis / Neoplasias Tipo de estudio: Risk_factors_studies Límite: Animals Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article País de afiliación: Suecia

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Mielopoyesis / Neoplasias Tipo de estudio: Risk_factors_studies Límite: Animals Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article País de afiliación: Suecia